MAGNEVIST

Indications

• Attention Deficit Hyperactivity Disorder (ADHD)
• Cognitive impairment in neurodegenerative diseases
• Alzheimer's disease
• Dementia
• Enhancement of cognitive function

Dosage

Children: Paediatric dosing should be determined based on clinical guidelines, considering the child's age, weight, and specific needs. Consultation of paediatric dosing references or healthcare professionals is advised for precise dosages.

Adults: The dosing regimen for dimesgumine should be tailored to the individual, taking into account the specific condition being treated and the patient's response. It is important to refer to established guidelines or clinical protocols for specific dosing recommendations.

Mechanism of action

Dimesgumine acts as a selective inhibitor of the enzyme acetylcholinesterase, which increases the levels of acetylcholine in the synaptic cleft. This enhancement in acetylcholine concentration facilitates improved synaptic transmission and promotes cognitive function. Additionally, dimesgumine may influence dopaminergic and adrenergic pathways, contributing to its stimulant effects.

Pharmacodynamics

The pharmacodynamics of dimesgumine involve its action on cholinergic receptors, leading to enhanced neurotransmission in areas of the brain associated with memory and attention. The increased availability of acetylcholine enhances synaptic activity, resulting in improved cognitive performance. The drug may also exhibit effects on norepinephrine and dopamine pathways, which are critical in mood regulation and alertness.

Pharmacokinetics

Dimesgumine is absorbed well after oral administration, with peak plasma concentrations typically occurring within a few hours. It is metabolized in the liver, and its metabolites are excreted primarily via the urine. The half-life of dimesgumine can vary, but it is generally considered to have a moderate duration of action, necessitating multiple doses throughout the day for sustained effects. The drug's pharmacokinetic profile may be influenced by factors such as age, liver function, and concurrent medications.

Pregnancy

There is insufficient data on the safety of dimesgumine during pregnancy. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether dimesgumine is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Indications

• Magnetic resonance imaging of the brain and spine
• Magnetic resonance angiography
• Assessment of tumors and other lesions
• Evaluation of vascular malformations

Dosage

Children: Refer to specific dosing guidelines as provided in professional references.

Adults: Refer to specific dosing guidelines as provided in professional references.

Mechanism of action

Gadopentetic acid functions as a contrast agent in MRI by shortening the T1 relaxation time of protons in the vicinity of the gadolinium ion. When injected into the body, it distributes into the extracellular space and enhances the magnetic resonance signal, providing clearer images of tissues and blood vessels. The paramagnetic properties of gadolinium ions allow for enhanced contrast due to their ability to affect the magnetic field around them.

Pharmacodynamics

The pharmacodynamics of gadopentetic acid are characterized by its ability to increase the signal intensity of tissues with high vascularization or lesions. The enhancement effect is dose-dependent, with higher concentrations resulting in greater contrast. The safety profile is generally favorable, but care must be taken in patients with renal impairment due to the risk of nephrogenic systemic fibrosis (NSF).

Pharmacokinetics

Gadopentetic acid is administered intravenously and is rapidly distributed in the extracellular fluid. It has a low protein binding affinity and is primarily excreted unchanged by the kidneys. The elimination half-life is approximately 1.5 hours in individuals with normal renal function, with complete renal clearance occurring within 24 hours. In patients with renal impairment, the elimination is significantly prolonged, necessitating caution in this population.

Contra-indications

• Severe renal impairment (eGFR < 30 mL/min)
• History of hypersensitivity reactions to gadolinium-based contrast agents
• Pregnancy (unless clearly necessary)

Adverse effects

• Nausea
• Headache
• Dizziness
• Hypotension
• Allergic reactions (including anaphylaxis)
• Nephrogenic systemic fibrosis (in patients with severe renal impairment)

Interactions

• Caution with other nephrotoxic agents
• May interact with medications that affect renal function

Precautions

• Assess renal function prior to administration
• Monitor patients for signs of allergic reactions
• Use with caution in patients with a history of asthma or allergies

Pregnancy

Gadopentetic should only be used in pregnancy if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Gadopentetic is excreted in human milk; caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from light. Do not freeze. Discard any unused portion after use.

Formulations

• Injection solution for intravenous use

Indications

• Fluid and electrolyte replenishment
• Management of hyponatremia
• Induction of abortion in specific medical circumstances

Dosage

Children: Refer to the BNF for Children for appropriate dosing information for pediatric patients.

Adults: Refer to the BNF for specific dosing guidelines based on clinical context and condition being treated.

Mechanism of action

Sodium and chloride, as major electrolytes in the extracellular fluid, work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations are linked to disorders of water balance. Intra-amniotic instillation of hypertonic sodium chloride may induce uterine contractions, leading to abortion, potentially mediated by prostaglandins released from damaged decidual cells.

Pharmacodynamics

Sodium, the principal cation in extracellular fluid, is critical for regulating water distribution, fluid balance, and osmotic pressure in body fluids. It works in conjunction with chloride and bicarbonate to maintain acid-base equilibrium. Chloride, as the major extracellular anion, mirrors sodium metabolism, and alterations in acid-base balance are reflected in chloride concentrations.

Pharmacokinetics

Sodium and chloride ions are absorbed from the gastrointestinal tract and distributed throughout the body fluids. Their concentration in extracellular fluid is tightly regulated by mechanisms involving renal excretion and hormonal control, primarily through aldosterone. Changes in dietary intake can also influence sodium levels significantly.

Pregnancy

Intra-amniotic instillation of hypertonic sodium chloride is associated with abortion and fetal death. Caution is advised during pregnancy.

Breast-feeding

Sodium is considered safe during breastfeeding as it is an essential electrolyte.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• 20% sodium chloride injection

Mechanism of action

Sodium and chloride - major electrolytes of the fluid compartment outside of cells (i.e., extracellular) - work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance. Intra-amniotic instillation of 20% sodium chloride injection induces abortion and fetal death. Although the mechanism has not been conclusively determined, some studies indicate that the drug's abortifacient activity may be mediated by prostaglandins released from decidual cells damaged by hypertonic solutions of sodium chloride. Hypertonic sodium chloride-induced uterine contractions are usually sufficient to cause evacuation of both the fetus and placenta; however, abortion may be incomplete in 25-40% of patients. /20% injection/

Pharmacodynamics

Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid. Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration.